Sanofi’s Anti-OX40 Blocker Falls ‘Well Below Expectations’ in Phase III Eczema Study – BioSpace eczemarelief 1 year ago Share Sanofi’s Anti-OX40 Blocker Falls ‘Well Below Expectations’ in Phase III Eczema Study BioSpace Source link